WASHINGTON, November 18, 2026 — President Donald Trump’s administration has withdrawn Dr. Heidi Overton’s nomination to lead the Food and Drug Administration, ending a contentious confirmation effort just hours before a scheduled Senate committee vote. The White House concluded that Overton lacked sufficient support among Republican senators, according to people familiar with the decision, while Senate Health Committee Chairman Bill Cassidy said he believed she could have passed and accused the administration of abandoning a viable path to confirmation. The withdrawal was reported by Reuters, The Associated Press and The Guardian.

Overton, a physician and deputy director of the White House Domestic Policy Council, was nominated in August after former FDA Commissioner Marty Makary left the agency in May. Her confirmation process had become increasingly difficult as senators from both parties questioned whether she would act independently of the president and Health Secretary Robert F. Kennedy Jr. The Senate Health, Education, Labor and Pensions Committee had scheduled a vote on her nomination for November 18, but the White House withdrew its support the previous evening. CBS News, The Washington Post and Reuters reported the decision and the background to her nomination.
The disagreement over the withdrawal was immediate. Cassidy said he had been having productive conversations with committee members and believed Overton had enough votes to advance through the committee and the full Senate. He said the remaining obstacle involved requests from anti-abortion senators for assurances from the administration on abortion-related policy. The White House’s reported position was that Overton did not have the votes needed for confirmation. The competing accounts show that the decision was not simply a routine end to a nomination; it exposed a dispute within the Republican coalition over the administration’s health agenda. CBS News’ account of Cassidy’s statement, The Guardian and AP detail the differing explanations.

Overton’s positions on vaccines were a major part of the scrutiny. At her September 24 confirmation hearing, Cassidy questioned her support for a Trump administration plan to change the childhood vaccination schedule and separate the combined measles, mumps and rubella vaccine into individual shots. Cassidy had described that support as nearly disqualifying, while Overton told the committee that the combined MMR vaccine was safe and effective. The hearing record provides a direct account of the exchange and the questions about her scientific independence. The Senate HELP Committee’s hearing material, AP and The Guardian describe the vaccine-policy dispute.
Her views on reproductive health regulation also became a point of contention. Overton had previously written a policy brief calling for stricter regulation of mifepristone, the medication used in most medication abortions in the United States, and criticised policies that allow abortion pills to be mailed. As FDA commissioner, she would have overseen the agency’s regulation of the drug, including its safety requirements and distribution rules. Reproductive-rights groups opposed her nomination, while Cassidy said anti-abortion senators sought assurances from the administration before the committee vote. The Guardian’s report, The Washington Post and CBS News outline the debate.

Other issues also complicated the nomination. Some Republican senators questioned Overton’s position on flavoured e-cigarettes after the FDA authorised certain fruit-flavoured products for adult smokers. Separately, prominent supporters of Kennedy’s Make America Healthy Again movement argued that Overton was not sufficiently committed to their priorities and questioned her approach to corporate influence and chemical regulation. Those objections came from different political directions: some lawmakers worried about her relationship with Trump’s health agenda, while some of Kennedy’s allies believed she would not push that agenda far enough. The Washington Post, AP and CBS News reported the different sources of opposition.
The FDA remains under acting Commissioner Kyle Diamantas, with no permanent replacement announced at the time of publication. Reuters reported that the White House was considering Senator Roger Marshall, a former obstetrician from Kansas, as a possible alternative, although the administration had not formally announced a new nominee. The agency has been without a Senate-confirmed commissioner since Makary’s departure in May and has faced staff losses and internal disputes over regulatory priorities. Reuters, AP and CBS News reported the leadership situation and possible next steps.
The leadership vacancy matters because the FDA regulates medicines, vaccines, medical devices, food safety and tobacco products that affect millions of Americans. A permanent commissioner must manage scientific review, enforcement, public-health emergencies and the agency’s relationship with the pharmaceutical and food industries. The White House’s next choice will face the same Senate questions about scientific independence, abortion medication, vaccine policy and the agency’s ability to make decisions based on evidence. The FDA’s official description of the Office of the Commissioner, AP and Reuters provide context on the agency’s responsibilities and leadership challenge.
HeadlinesXtra Analysis
Overton’s withdrawal illustrates the difficulty of appointing a regulator when scientific independence, ideological commitments and political loyalty are all being tested at the same time. The FDA commissioner is expected to implement the administration’s lawful priorities, but the agency’s credibility also depends on decisions that are transparent, evidence-based and consistent with statutory standards. Senators from both parties were entitled to question whether the nominee would be able to resist political pressure when evaluating vaccines, medicines and other regulated products.
The conflicting explanations for the withdrawal are also significant. The White House reportedly concluded that Overton could not secure enough votes, while Cassidy said he believed she had a viable path and that the administration chose not to provide assurances sought by anti-abortion senators. Without a public vote or a formal explanation from all the participants, the precise balance of political and policy considerations remains disputed. The competing accounts should not be collapsed into a single definitive explanation.
The next nominee will inherit an agency facing leadership uncertainty, staff losses and public disagreement over vaccines, reproductive health and tobacco regulation. Restoring confidence will require more than a successful confirmation vote: the commissioner will need to demonstrate independence, communicate scientific decisions clearly and ensure that public-health protections are applied consistently. The Senate’s scrutiny of the next nominee will be an important test of whether those standards can be maintained.
Sources and Further Reading
- Reuters — Trump withdraws Heidi Overton as nominee to lead the FDA
- Associated Press — White House pulls FDA nominee Heidi Overton after wavering support from Senate Republicans
- The Guardian — White House withdraws Heidi Overton’s nomination to lead FDA
- The Washington Post — White House pulls FDA nominee amid political pushback
- CBS News — White House drops Heidi Overton’s nomination for FDA commissioner
- U.S. Senate HELP Committee — Chairman Cassidy’s remarks during Overton’s confirmation hearing, September 24, 2026
- U.S. Food and Drug Administration — Office of the Commissioner